May 4, 2022

Featuring an interview with Dr David O'Malley, including the following topics:

• Efficacy and safety data with mirvetuximab soravtansine for ovarian cancer (OC) from the SORAYA trial (0:00)
• Potential integration of mirvetuximab soravtansine into clinical practice; biologic rationale for and mechanism of action of upifitamab rilsodotin in therapy for OC (6:30)
• Rationale for using tumor treating fields in combination with paclitaxel for OC; efficacy data with tumor treating fields for thoracic mesothelioma and glioblastoma multiforme (12:45)
• Ongoing work on quantitative tests to identify patients most likely to benefit from PARP inhibitors; real-world treatment patterns in OC (21:27)
• Single-agent neoadjuvant niraparib; emerging data with niraparib/bevacizumab and potential integration into treatment algorithms (28:46)
• PARP inhibitors in patients with BRCA wild-type OC; design, similarities and differences from the PRIME and PRIMA trials of maintenance niraparib (36:02)
• Ongoing MONO-OLA1 trial of olaparib with and without bevacizumab as up-front treatment for OC; final overall survival and second progression-free survival data from the SOLO-3 trial (42:28)

CME information and select publications